As of May 23
| +0.01 / +0.21%|
The 4 analysts offering 12-month price forecasts for CTi Biopharma Corp have a median target of 7.00, with a high estimate of 10.00 and a low estimate of 5.00. The median estimate represents a +46.14% increase from the last price of 4.79.
The current consensus among 4 polled investment analysts is to Buy stock in CTi Biopharma Corp. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.